All News
Quality patient communication is actually critical to outcome #EULAR2022 @RheumNow https://t.co/37Z7hwrWmX
David Liew drdavidliew ( View Tweet)
What's the argument against that?
Fundamentally, empathy. The patient experience isn't just a product of miracle drugs - over time it's a multitude of factors that are what leads to happy patients
#EULAR2022 @RheumNow https://t.co/8GwhdT8cit
David Liew drdavidliew ( View Tweet)
and if we don't act, we leave it to the wild, wild west of the private market:
- designed for profit (not necessarily bad)
- but often at the cost of robust dedication to patient outcomes (always bad)
#EULAR2022 @RheumNow https://t.co/zfJWTZ3I1G
David Liew drdavidliew ( View Tweet)
In fact, in some select situations we can get by very well without seeing our patient at all?
#EULAR2022 @RheumNow https://t.co/4qcaj2KR9B
David Liew drdavidliew ( View Tweet)
So maybe telemedicine can bring us the efficiency that we badly need. In rheumatology, we're drowning in demand - is telemedicine part of the solution?
#EULAR2022 @RheumNow https://t.co/kHBIYRIvBA
David Liew drdavidliew ( View Tweet)
✨ Inflammatory #Myositis✨
👉 Excellent summary of Autoantibodies, Immune alterations and Distinct Phenotypes by Dr. Lisa Rider
#EULAR2022 https://t.co/KLzmLUGk9Z
Ashima Makol MD AshimaMakol ( View Tweet)
Watch: New 2022 EULAR RA Treatment Guidelines
https://t.co/mF4cKJLtbr
#EULAR2022 https://t.co/oI8p6gL0Tf
Links:
Dr. John Cush RheumNow ( View Tweet)
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Links:
Richard Conway RichardPAConway ( View Tweet)
Manzi et al. Data on anifrolumab from TULIP studies on depression/suicidality. No effect. @RheumNow #EULAR2022 OP0282 https://t.co/5n7HBqzLkX https://t.co/fq4dxskJaA
Links:
Richard Conway RichardPAConway ( View Tweet)
Roberto Giacomeilli from Italy explaining the mechanisms on how COVID-19 may cause rheumatic disease #EULAR2022 @RheumNow https://t.co/a2kTT7vcRx
Dr. Antoni Chan synovialjoints ( View Tweet)
Nossent et al Hospitalisation with opportunistic infection twice as high in RA vs AxSpA/PsA. Has IMPROVED over biologic era. To me, suggests benefits of proper disease control on infection risk
@RheumNow
#EULAR2022 OP0274 https://t.co/cqUoRti4We https://t.co/Ozz7jH3z4N
Links:
Richard Conway RichardPAConway ( View Tweet)
Catching up with Jack, a great teacher and educator @RheumNow #rheum #rheumedu #EULAR2022 https://t.co/2wqbhpIb2P
Dr. Antoni Chan synovialjoints ( View Tweet)
LDA/MDA achieved in 60% of PsA pts on (mostly) bDMARDs. Combo baseline features: TJC>3, SJC>5, CRP>10 mg/l, HAQ>0.5, enthesitis, dactylitis, BMI>30 & sDMARDs tx constitutes negative predictive impact on MDA/LDA after 1 yr. #EULAR2022 POS0080 @RheumNow https://t.co/PugwiuSMPm https://t.co/nqadEjA3Xe
Dr. Rachel Tate uptoTate ( View Tweet)
Izokibep - potent and small molecule IL-17A inhibitor Phase 2 study in PsA patients
Fast onset, met ACR50 primary endpoint
AE included site reaction and candida infection
@RheumNow #EULAR2022 ABST#OP0258 https://t.co/vZ4xmnhyhl
Robert B Chao, MD doctorRBC ( View Tweet)
I could listen to Dennis McGonagle talk about enthesitis all day.
If you missed it, one to check out later #EULAR2022 @RheumNow https://t.co/8pRKqMB06j
David Liew drdavidliew ( View Tweet)
Add on MTX does not impair UST immunogenicity in PsA. #EULAR2022 POS0079 @RheumNow
https://t.co/CalEn7KpsX https://t.co/NZUqdX0XKo
Dr. Rachel Tate uptoTate ( View Tweet)
52 wk trial using MSK Ultrasound study on PsA receiving secukinumab showed an early and continued improvement in GLOESS scores.
Synovial hypertrophy most responsive.
Hands and feet, wrist and knees most affected and responsive.
@RheumNow #EULAR2022 ABST#OP0260 https://t.co/jeQezIWLxa
Robert B Chao, MD doctorRBC ( View Tweet)
#POS0757 #EULAR2022 What is the perception of #lupus patients on #COVID19 recovery? A survey of 202 pts from BILAG-BR (N=20 case+, 3 hospitalised) reported full recovery from covid in only 1/3 of patients. These pts would need extra support @RheumNow https://t.co/SdH223Lfoa
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Novel composite DAPSA LDA +IGA < or = to 1 may be a reliable predictor in long-term PsA skin/joint response (and easier to get than PASDAS in clinic.) @AlexisOgdie #EULAR2022 POS0082 @RheumNow https://t.co/dmMjGcsIcm https://t.co/BHRlGenCyl
Dr. Rachel Tate uptoTate ( View Tweet)
Style guide: welcome to the modern era of #EULAR2022
(and here I am, stuck-in-the-mud still wearing my collared shirt/blue blazer)
@RheumNow https://t.co/MXXHWF7Q47
David Liew drdavidliew ( View Tweet)